Clinical trial
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
NCT01260649 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- November 1, 2010
- Completion date
- November 1, 2012
- Enrollment
- 17 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.